TYRA - NASDAQ
Tyra Biosciences, Inc.
$26.60
-7.3%Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
At a Glance
Live SnapshotTyra Biosciences, Inc. Management Team
Dr. Piyush R. Patel Ph.D.
Chief Development Officer
Dr. Douglas Warner M.D.
Chief Medical Officer
Compensation
$627,900
Dr. Ronald V. Swanson Ph.D.
Chief Scientific Officer
Compensation
$536,188
Dr. Robert L. Hudkins Ph.D.
Chief Technology Officer
Mr. Daniel Bensen
Co-Founder & Chief Operating Officer
Compensation
$737,643
Dr. Todd Harris Ph.D.
Co-Founder, President, Chief Executive Officer, Secretary, Treasurer & Director
Compensation
$1,067,050
Mr. Ali D. Fawaz J.D.
General Counsel
Compensation
$629,230
Mr. Erik Goluboff
Senior Vice President of Clinical Development
Ms. Sarah Honig
Senior Vice President of Corporate Development & Strategy
Liz Pagano
Senior Vice President of Human Resources
Tyra Biosciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $27.26M and sold $10.97M worth of TYRA shares, resulting in $16.29M of net buying activity.
3 Months
0
0.00
14.3K
528.51K
-529K
-$529K
3-6 Months
0
0.00
27.1K
696.80K
-697K
-$697K
6-9 Months
701
6.40K
502.4K
9.11M
-9.1M
-$9.11M
9-12 Months
2.7M
27.25M
61.4K
628.26K
+26.6M
+$26.62M
Top Buyers
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$15.32M
Harris Todd
Director, Officer: President And Ceo
$6.13M
Warner Douglas J
Officer: Chief Medical Officer
$2.15M
Fuhrman Alan
Officer: Chief Financial Officer
$1.83M
Bensen Daniel
Officer: Chief Operating Officer
$1.83M
Top Sellers
More Robert J
Director
$5.25M
Bensen Daniel
Officer: Chief Discovery Officer
$4.56M
Kaplan Gilla
Director
$1.16M
Insider Activity Analysis
Net Insider Sentiment
Positive insider sentiment with $16.29M net buying. Buying activity substantially exceeds selling, indicating insider confidence.
Buy/Sell Ratio
Strong buy/sell ratio. Buying is at least double the selling activity, suggesting robust insider confidence.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 3 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
TYRA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 17, 2026 | May 28, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 18, 2025 | May 29, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 18, 2024 | May 29, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 17, 2023 | May 31, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 13, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.